Lillian Skidmore

机构：Legambiente, Ambrx (United States) · ORCID：0009-0005-8277-8223

发表论文 47 篇 · 总被引 438 次 · h-index 6

代表论文

• Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer (2024 · Molecular Cancer Therapeutics · 被引 19)
• Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development (2023 · PLoS ONE · 被引 9)
• Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle (2024 · Frontiers in Microbiology · 被引 5)
• Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer (2023 · Cancer Research · 被引 5)
• 1828P ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01) (2023 · Annals of Oncology · 被引 4)
• 41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models (2023 · Annals of Oncology · 被引 3)